GINKGO BIOWORKS HOLDINGS INCORPORATED (DNA)

Evotec (OTCMKTS:EVTCY – Get Free ... (NYSE:DNA – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and …

The Magnificent Seven turned patient investors into millionaires over the past decade, but the next decade of compounding belongs to a shorter list. Three stocks just posted beat-and-raise quarters and still have room to run.

Tempus shares ended the regular session at $44.28, up 6.57% from the previous close of $41.55. After the earnings release, the stock fell to $42.97 in after-hours trading, down $1.32, or 2.98%, from the regular-session close.

Ginkgo Bioworks will host a Q2 2026 business performance presentation and Q&A on August 5, 2026 at 4:30 p.m. ET, with webcast access and replay via its investor relations website.

Apple shares sink on disappointing September quarter sales outlook · Amazon shares surge as cloud growth surges and spending outlook climbs